148 related articles for article (PubMed ID: 21340193)
41. Clinical and biological relationship between chronic lymphocytic thyroiditis and papillary thyroid carcinoma.
Antonaci A; Consorti F; Mardente S; Giovannone G
Oncol Res; 2009; 17(10):495-503. PubMed ID: 19725229
[TBL] [Abstract][Full Text] [Related]
42. Pathologic spectrum of lymphocytic infiltration and recurrence of papillary thyroid carcinoma.
Kim HG; Kim EK; Han KH; Kim H; Kwak JY
Yonsei Med J; 2014 Jul; 55(4):879-85. PubMed ID: 24954314
[TBL] [Abstract][Full Text] [Related]
43. Death from thyroid cancer of follicular cell origin.
Wu HS; Young MT; Ituarte PH; D'Avanzo A; Duh QY; Greenspan FS; Loh KC; Clark OH
J Am Coll Surg; 2000 Dec; 191(6):600-6. PubMed ID: 11129807
[TBL] [Abstract][Full Text] [Related]
44. Role of chronic lymphocytic thyroiditis in central node metastasis of papillary thyroid carcinoma.
Paulson LM; Shindo ML; Schuff KG
Otolaryngol Head Neck Surg; 2012 Sep; 147(3):444-9. PubMed ID: 22547555
[TBL] [Abstract][Full Text] [Related]
45. Thyroid papillary carcinoma associated to Hashimoto's thyroiditis.
Campos LA; Picado SM; Guimarães AV; Ribeiro DA; Dedivitis RA
Braz J Otorhinolaryngol; 2012 Dec; 78(6):77-80. PubMed ID: 23306572
[TBL] [Abstract][Full Text] [Related]
46. Both gender and concurrent chronic lymphocytic thyroiditis may influence the nuclear texture of papillary thyroid carcinomas cells.
Cunha LL; Ferreira Rde C; de Matos PS; da Assumpção LV; Ward LS
Endocr Res; 2014; 39(3):126-9. PubMed ID: 24460065
[TBL] [Abstract][Full Text] [Related]
47. Long-term outcome of differentiated thyroid carcinoma: experience in a developing country.
Bhargav PR; Mishra A; Agarwal G; Agarwal A; Pradhan PK; Gambhir S; Verma AK; Mishra SK
World J Surg; 2010 Jan; 34(1):40-7. PubMed ID: 20020292
[TBL] [Abstract][Full Text] [Related]
48. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
[TBL] [Abstract][Full Text] [Related]
49. Risk Factors for Nodal Metastasis in cN0 Papillary Thyroid Microcarcinoma.
Zhang LY; Liu ZW; Liu YW; Gao WS; Zheng CJ
Asian Pac J Cancer Prev; 2015; 16(8):3361-3. PubMed ID: 25921145
[TBL] [Abstract][Full Text] [Related]
50. BRAF mutation is unusual in chronic lymphocytic thyroiditis-associated papillary thyroid carcinomas and absent in non-neoplastic nuclear atypia of thyroiditis.
Sargent R; LiVolsi V; Murphy J; Mantha G; Hunt JL
Endocr Pathol; 2006; 17(3):235-41. PubMed ID: 17308360
[TBL] [Abstract][Full Text] [Related]
51. FOXE1 association with differentiated thyroid cancer and its progression.
Penna-Martinez M; Epp F; Kahles H; Ramos-Lopez E; Hinsch N; Hansmann ML; Selkinski I; Grünwald F; Holzer K; Bechstein WO; Zeuzem S; Vorländer C; Badenhoop K
Thyroid; 2014 May; 24(5):845-51. PubMed ID: 24325646
[TBL] [Abstract][Full Text] [Related]
52. Single Point Mutations in Pediatric Differentiated Thyroid Cancer.
Alzahrani AS; Murugan AK; Qasem E; Alswailem M; Al-Hindi H; Shi Y
Thyroid; 2017 Feb; 27(2):189-196. PubMed ID: 27824297
[TBL] [Abstract][Full Text] [Related]
53. Non-suppressed thyrotropin and elevated thyroglobulin are independent predictors of recurrence in differentiated thyroid carcinoma.
Böhm J; Kosma VM; Eskelinen M; Hollmen S; Niskanen M; Tulla H; Alhava E; Niskanen L
Eur J Endocrinol; 1999 Nov; 141(5):460-7. PubMed ID: 10576761
[TBL] [Abstract][Full Text] [Related]
54. Effect of Tumor Size on Risk of Metastatic Disease and Survival for Thyroid Cancer: Implications for Biopsy Guidelines.
Nguyen XV; Roy Choudhury K; Tessler FN; Hoang JK
Thyroid; 2018 Mar; 28(3):295-300. PubMed ID: 29373949
[TBL] [Abstract][Full Text] [Related]
55. Disparities in the initial presentation of differentiated thyroid cancer in a large public hospital and adjoining university teaching hospital.
Lim II; Hochman T; Blumberg SN; Patel KN; Heller KS; Ogilvie JB
Thyroid; 2012 Mar; 22(3):269-74. PubMed ID: 22233131
[TBL] [Abstract][Full Text] [Related]
56. Dynamic Risk Stratification for Predicting Recurrence in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy.
Park S; Kim WG; Song E; Oh HS; Kim M; Kwon H; Jeon MJ; Kim TY; Shong YK; Kim WB
Thyroid; 2017 Apr; 27(4):524-530. PubMed ID: 27869547
[TBL] [Abstract][Full Text] [Related]
57. Papillary Thyroid Carcinoma Emerging from Hashimoto Thyroiditis Demonstrates Increased PD-L1 Expression, Which Persists with Metastasis.
Lubin D; Baraban E; Lisby A; Jalali-Farahani S; Zhang P; Livolsi V
Endocr Pathol; 2018 Dec; 29(4):317-323. PubMed ID: 30121940
[TBL] [Abstract][Full Text] [Related]
58. Coexistence of papillary carcinoma and Hashimoto's thyroiditis.
Matesa-Anić D; Matesa N; Dabelić N; Kusić Z
Acta Clin Croat; 2009 Mar; 48(1):9-12. PubMed ID: 19623865
[TBL] [Abstract][Full Text] [Related]
59. Total thyroidectomy without prophylactic central neck dissection in clinically node-negative papillary thyroid cancer: is it an adequate treatment?
Calò PG; Pisano G; Medas F; Marcialis J; Gordini L; Erdas E; Nicolosi A
World J Surg Oncol; 2014 May; 12():152. PubMed ID: 24885654
[TBL] [Abstract][Full Text] [Related]
60. Association between chronic lymphocytic thyroiditis and papillary thyroid carcinoma: A retrospective study in surgical specimens.
Osorio C; Ibarra S; Arrieta J; Sarmiento M; Barrios D; Sierra L; Redondo K; Francisco Herrera
Rev Esp Patol; 2020; 53(3):149-157. PubMed ID: 32650966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
